Consensus Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
93 ^USD	+2.50%		+7.08%	+0.82%

25/04	Transcript : Blueprint Medicines Corporation - Special Call
22/03	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Blueprint Medicines Corporation

Price target over the last 5 years

History of analyst recommendation changes

c6cb7db6903179c17f7f368b0c6307.HY72NnChJ3HPR6A7c9U1V7RWFl1DukbylJh7m4Z_B3I.X-i6RSPRcwmHKudKKZZSPv9jThw6gi6E06gv2PQ9fxQkx5pQH5FRAPo39Q~d19bef9483d4f8157f67e265068c3600

Analyst Recommendations on Blueprint Medicines Corporation

Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	15/02	MT
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	13/02	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	31/01	MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating	09/01	MT
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating	08/01	MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating	22/12	MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating	19/12	MT
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating	11/12	MT
North American Morning Briefing : Rate Decisions, -2-	30/23/30	DJ
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating	27/23/27	MT
Barclays Raises Price Target on Blueprint Medicines to $58 From $46, Maintains Equalweight Rating	27/23/27	MT
Needham Raises Blueprint Medicines Price Target to $74 From $66, Maintains Buy Rating	27/23/27	MT
Oppenheimer Upgrades Blueprint Medicines to Outperform From Perform, $85 Price Target	27/23/27	MT
Wedbush Raises Blueprint Medicines' Price Target to $80 From $75 After Higher-Than-Expected Q3 Financial Results, Keeps Outperform Rating	26/23/26	MT
Needham Adjusts Price Target on Blueprint Medicines to $66 From $65, Maintains Buy Rating	21/23/21	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $83 From $93, Maintains Buy Rating	03/23/03	MT
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $59 From $55, Maintains Equal-Weight Rating	03/23/03	MT
Wells Fargo Upgrades Blueprint Medicines to Overweight From Equalweight, Adjusts Price Target to $82 From $55	31/23/31	MT
Wells Fargo Raises Price Target on Blueprint Medicines to $55 From $48, Maintains Equal-Weight Rating	14/23/14	MT
SVB Securities Downgrades Blueprint Medicines to Underperform From Market Perform, Cuts Price Target to $43 From $48	05/23/05	MT
Guggenheim Raises Price Target on Blueprint Medicines to $82 From $78, Maintains Buy Rating	23/23/23	MT
SVB Securities Adjusts Price Target on Blueprint Medicines to $48 From $45, Maintains Market Perform Rating	23/23/23	MT
Wells Fargo Adjusts Price Target on Blueprint Medicines to $48 From $47, Keeps Equalweight Rating	23/23/23	MT
HC Wainwright Adjusts Blueprint Medicines' Price Target to $85 From $75, Keeps Buy Rating	23/23/23	MT
Needham Adjusts Blueprint Medicines' Price Target to $67 From $65, Keeps Buy Rating	23/23/23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

93 USD

Average target price

98.06 USD

Spread / Average Target

+5.44%

High Price Target

130 USD

Spread / Highest target

+39.78%

Low Price Target

50 USD

Spread / Lowest Target

-46.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Blueprint Medicines Corporation

Wedbush
Barclays
Oppenheimer
Stifel Nicolaus
Raymond James
Wells Fargo Securities
Morgan Stanley
Needham & Co.
Goldman Sachs
SVB Securities LLC
Guggenheim
HC Wainwright
Berenberg Bank
Jefferies & Co.
Citigroup
Piper Sandler
Baird
SVB Leerink
Credit Suisse

Ratings for Blueprint Medicines Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar